MannKind Corp (MNKD)
4.21
+0.06
(+1.45%)
USD |
NASDAQ |
Apr 24, 10:31
MannKind Research and Development Expense (Quarterly): 9.236M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 9.236M |
| September 30, 2023 | 9.989M |
| June 30, 2023 | 6.453M |
| March 31, 2023 | 5.605M |
| December 31, 2022 | 7.156M |
| September 30, 2022 | 4.136M |
| June 30, 2022 | 4.893M |
| March 31, 2022 | 3.536M |
| December 31, 2021 | 3.886M |
| September 30, 2021 | 3.655M |
| June 30, 2021 | 2.329M |
| March 31, 2021 | 2.442M |
| December 31, 2020 | 1.545M |
| September 30, 2020 | 1.484M |
| June 30, 2020 | 1.464M |
| March 31, 2020 | 1.755M |
| December 31, 2019 | 2.021M |
| September 30, 2019 | 1.58M |
| June 30, 2019 | 1.632M |
| March 31, 2019 | 1.667M |
| December 31, 2018 | 1.084M |
| September 30, 2018 | 2.043M |
| June 30, 2018 | 2.967M |
| March 31, 2018 | 2.644M |
| December 31, 2017 | 3.507M |
| Date | Value |
|---|---|
| September 30, 2017 | 4.361M |
| June 30, 2017 | 3.123M |
| March 31, 2017 | 3.129M |
| December 31, 2016 | 1.56M |
| September 30, 2016 | 3.917M |
| June 30, 2016 | 4.31M |
| March 31, 2016 | 5.13M |
| December 31, 2015 | 6.219M |
| September 30, 2015 | 6.341M |
| June 30, 2015 | 7.737M |
| March 31, 2015 | 9.377M |
| December 31, 2014 | 17.56M |
| September 30, 2014 | 19.18M |
| June 30, 2014 | 37.32M |
| March 31, 2014 | 26.18M |
| December 31, 2013 | 28.99M |
| September 30, 2013 | 27.28M |
| June 30, 2013 | 27.05M |
| March 31, 2013 | 26.40M |
| December 31, 2012 | 25.28M |
| September 30, 2012 | 25.45M |
| June 30, 2012 | 26.64M |
| March 31, 2012 | 24.16M |
| December 31, 2011 | 20.24M |
| September 30, 2011 | 23.13M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.464M
Minimum
Jun 2020
9.989M
Maximum
Sep 2023
3.937M
Average
3.536M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Cassava Sciences Inc | 18.73M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |
| Theriva Biologics Inc | 4.196M |